gomisin K1 | 75684-44-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 英文名称: gomisin K1
• 英文别名: Gomisin K2, (+)-；(9S,10R)-3,4,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-5-ol
• CAS: 75684-44-5；75629-20-8
• 化学式: C₂₃H₃₀O₆
• 分子量: 402.488
• InChiKey: RCPUCQCVTDMJGJ-QWHCGFSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  gomisin K1 、 硫酸二甲酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 3.0h， 生成 schisandrin A
  参考文献：
  名称：

  Ikeya, Yukinobu; Taguchi, Heihachiro; Yosioka, Itiro, Chemical and pharmaceutical bulletin, 1980, vol. 28, # 8, p. 2422 - 2427

  摘要：

  DOI：
• 作为产物：
  描述：

  gomisin K1 acetate 在 氢氧化钾 、 乙醇 作用下， 反应 2.0h， 生成 gomisin K1
  参考文献：
  名称：

  Ikeya, Yukinobu; Taguchi, Heihachiro; Yosioka, Itiro, Chemical and pharmaceutical bulletin, 1980, vol. 28, # 8, p. 2422 - 2427

  摘要：

  DOI：

文献信息

• Structure-Activity Relationships of Lignans from Schisandra chinensis as Platelet Activating Factor Antagonists.
  作者：Im Seon LEE、Keun Young JUNG、Sei Ryang OH、Si Hyung PARK、Kyung Seop AHN、Hyeong-Kyu LEE

  DOI：10.1248/bpb.22.265

  日期：——

  structure-activity relationships of lignans from Schisandra chinensis and their derivatives as platelet activating factor (PAF) antagonists. Strong activity was shown in lignans without an ester group at C-6, a hydroxyl group at C-7 or a methylene dioxy moiety and with an R-biphenyl configuration. 6(7)-Dehydroschisandrol A, a derivative of schisandrol A, showed the highest activity (IC50, 2.1x10(-6) M) in this

  我们研究了五味子的木脂素及其衍生物作为血小板活化因子（PAF）拮抗剂的构效关系。在木脂素中显示出强活性，其在C-6处没有酯基，在C-7处没有羟基或亚甲基二氧基部分并且具有R-联苯基构型。五倍子A的衍生物6（7）-脱氢五倍子A表现出最高的活性（IC50，2.1x10（-6）M）。
• Methods of application of chemical compounds having therapeutic activities in treating cancers
  申请人：Hu Xun

  公开号：US20050282910A1

  公开（公告）日：2005-12-22

  Methods of application of a class of compounds with a pharmacophore of dibenzocyclooctadiene in the preparation of anticancer medications, and particularly for the preparation of medications for the treatment of P-glycoprotein-mediated multidrug resistant (MDR) cancer and non-P-glycoprotein-mediated MDR cancer, such as multidrug resistant associated protein MRP1-mediated cancer. Methods of increasing the efficacy of anticancer agents are further disclosed. The class of compounds are of a potency to effectively reverse MDR cancer by inhibiting the drug transport activity of an ABC drug transporter, increase the intracellular accumulation of an anticancer agent in MDR cancer cells, enhance apoptosis of cancer cells induced by an anticancer agent, and directly kill cancer cells. The aforementioned methods of application of the present disclosure provide much potential for the treatment of cancer. Mass production of medications incorporating these chemical compounds will treat a significant number of patients affected by the condition of MDR cancer.
• [EN] METHODS OF APPLICATION OF CHEMICAL COMPOUNDS HAVING THERAPEUTIC ACTIVITIES IN TREATING CANCERS<br/>[FR] PROCEDES D'APPLICATION DE COMPOSES CHIMIQUES A ACTIVITES THERAPEUTIQUES DANS LE TRAITEMENT DES CANCERS
  申请人：WANG HAIBIN

  公开号：WO2007005760A1

  公开（公告）日：2007-01-11

  [EN] Methods of application of a class of compounds with a pharmacophore of dibenzocyclooctadiene in the preparation of anticancer medications, and particularly for the preparation of medications for the treatment of P-glycoprotein-mediated multidrug resistant (MDR) cancer and non-P-glycoprotein-mediated MDR cancer, such as multidrug resistant associated protein MRPl -mediated cancer. Methods of increasing the efficacy of anticancer agents are further disclosed. The class of compounds are of a potency to effectively reverse MDR cancer by inhibiting the drug transport activity of an ABC drug transporter, increase the intracellular accumulation of an anticancer agent in MDR cancer cells, enhance apoptosis of cancer cells induced by an anticancer agent, and directly kill cancer cells . The aforementioned methods of application of the present disclosure provide much potential for the treatment of cancer. Mass production of medications incorporating these chemical compounds will treat a significant number of patients affected by the condition of MDR cancer.
  [FR] Ces procédés d'application d'un type de composé avec un pharmacophore de dibenzocyclooctadiène dans la préparation de médicaments contre le cancer, et particulièrement dans la préparation de médicaments pour le traitement du cancer multirésistant aux antibiotiques induits par P-glycoprotéine (MDR) et du cancer MDR non induit par P-glycoprotéine, notamment un cancer induit par la protéine MRP1 et multirésistante aux antibiotiques. Les procédés d'augmentation de l'efficacité des agents anticancéreux font intervenir le type de composés puissants pour inverser efficacement le cancer MDR en inhibant l'activité de transport de médicament d'un transporteur de médicament ABC, augmenter l'accumulation intracellulaire d'un agent anticancéreux dans les cellules cancéreuses MDR, augmenter l'apoptose de cellules cancéreuses induite par un agent anticancéreux, et éliminer directement les cellules cancéreuses. Les procédés précités sont très prometteurs pour le traitement du cancer. La production massive de médicaments intégrant ces composés chimiques permettra de traiter un nombre important de malades souffrant du cancer MDR.
• Ikeya, Yukinobu; Taguchi, Heihachiro; Yosioka, Itiro, Chemical and pharmaceutical bulletin, 1980, vol. 28, # 8, p. 2422 - 2427
  作者：Ikeya, Yukinobu、Taguchi, Heihachiro、Yosioka, Itiro

  DOI：——

  日期：——